Thank you for participating in BIO-Europe Spring^® 2012

2,157 attendees from 1,304 companies participated in 11,172 one-to-one meetings and
135 company presentations on products and technologies.

Impressions of BIO-Europe Spring ►

Save the date and check back in the coming weeks for information on next year's BIO-Europe Spring^®, March 11–13, 2013 in Barcelona, Spain.

Use partnering360^® to:

Follow up and stay in touch with people you met at BIO-Europe Spring
Access an archive of all meeting requests your company has sent and received at any partneringONE^® event
See which conferences your contacts will attend next

Log in to your BIO-Europe Spring partneringONE account ►
View impressions of BIO-Europe Spring ►
See videos of BIO-Europe Spring ►
Tell us about your BIO-Europe Spring experience ►

One-to-one meetings
Sessions
Company presentations
Exhibition
partnering360
Online company presentations

One-to-one meetings partneringONE^® enables participants to identify and select potential partners. The system—industry-specific, web-based and interactive—is uniquely suited for the needs of life science companies. more ►

Sessions Panels and workshops feature corporate leaders who share insight, opinion and advice on how to navigate industry challenges. more ►

Company presentations Select biotechnology, midsize and big pharmaceutical companies present their products and technologies and corporate strategies in 14-minute presentations. more ►

Exhibition A lively exhibition in the heart of the conference area showcases companies, services and technologies. more ►

partnering360 Boost your partnering productivity year round. Showcase assets. Market products and ideas. Meet us at booth #64, and keep your network active on partnering360! more ►

Online company presentations Breaking through the noise just got a whole lot easier! Let us prepare an online company presentation for you during BIO-Europe Spring. more ►

About the BIO-Europe Spring^® Conference

BIO-Europe Spring 2012 Highlights

11,172 one-to-one meetings - up 21% over 2011
2,508 licensing opportunities
posted - up 13% over 2011
2,157 delegates - up 20% over 2011
1,304 companies - up 15% over 2011
135 company presentations
67 exhibitors
44 countries represented
18 workshops and panels

Photos of BIO-Europe Spring 2011 ►

Where the global biotech industry comes to partner

BIO-Europe Spring^® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe^®, and continues the tradition of providing life science companies with high caliber partnering opportunities.

Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE^®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.

more ►

Featured speakers

Vaughn Kailian
Managing Partner
MPM Capital

Roger Longman
CEO
Real Endpoints

Anna Protopapas
Executive VP
Global Business Development
Takeda Pharmaceuticals

Francesco De Rubertis
Partner
Index Ventures

Hans Schikan
CEO
Prosensa

Moncef Slaoui
Chairman R&D
GlaxoSmithKline

Paul Stoffels
Worldwide Chairman
Pharmaceuticals
Johnson & Johnson

Philip Vickers
Senior VP R&D
Shire Human Genetic Therapies

more ►

Company presentations

more ►

Conference videos

Next generation anticancer approaches: Innovation meets commercial realities20-Mar-12 | BIO-Europe Spring^® 2012This discussion focuses on how commercial realities meet innovation within oncology, covering challenges companies face as oncology becomes increasingly competitive. view "full session"

The assessment and management of assets: How to position the asset to attract a deal20-Mar-12 | BIO-Europe Spring^® 2012There is still a great deal to learn about how to better position an asset to attract investors or deal partners, with an understanding of both short and long term goals.view "full session"

Biotech business models for faster returns19-Mar-12 | BIO-Europe Spring^® 2012Nimble entrepreneurs are developing funds and corporate structures that may once again make private biotech an attractive investment, focusing on the drug, not the company.view "full session"

Close up and personal: Recent deals examined from both sides19-Mar-12 | BIO-Europe Spring^® 2012With special emphasis on Dutch biotech deals, executives discuss what the dealmaking hurdles were, what they learned from the process, and how the alliance has been managedview "full session"

Regional focus: Leveraging commercial rights for emerging markets19-Mar-12 | BIO-Europe Spring^® 2012Life science companies are shifting focus to take advantage of specialty indications and regional markets, such as China, the Middle East, Russia and South Americaview "full session"

Early stage financing: European and US VCs weigh in19-Mar-12 | BIO-Europe Spring^® 2012Is there a recipe for current VCs for successful investing in early stage science? Will recent initiatives from both government and industry help or hurt the venture industry?view "full session"

Advanced therapies: Stem cell and immunotherapy promises in practice19-Mar-12 | BIO-Europe Spring^® 2012This panel examines major clinical and commercial developments in using stem cells as drug discovery platforms, as well as the development of immunotherapies to treat cancer.view "full session"

Unconventional deals to herculean strategies19-Mar-12 | BIO-Europe Spring^® 2012New realities in healthcare have caused investors to lean toward non-traditional dealmaking strategies. Panelists explore multifaceted, powerful, even herculean, strategies.view "full session"

The opportunity of community drug development partnerships for personalized oncology and drug development19-Mar-12 | BIO-Europe Spring^® 2012Will community drug development partnerships among academic institutions, diagnostics companies, technology providers and bio/pharma lead to more effective cancer drugs?view "full session"

Are orphan indications the only viable model for drug development?19-Mar-12 | BIO-Europe Spring^® 2012The opening plenary addresses orphan indications as a viable model for drug development. Panelists discuss development strategies and the future of personalized medicine.view "full session"

Examining major deals of the past year19-Mar-12 | BIO-Europe Spring^® 2012Panelists examine significant deals of 2011, including what these deals reveal about pharma’s priorities, strategy and the options available to drug development companies.view "full session"